CMBI: Raises SBP GROUP (01177) Target Price to HK$9, Maintains "Buy" Rating

date
10:59 17/11/2026
avatar
GMT Eight
China Biopharmaceutical has recently continued to achieve breakthroughs in both the commercialization and internationalization of innovative drugs. Medicare expansion is expected to accelerate the commercial conversion of the company's innovative products, while its collaboration with Boehringer Ingelheim validates the value of the company's early-stage research platform.
CMBI issued a research report stating that it raises SBP GROUP's (01177) target price by 3.4%, from HK$8.7 to HK$9, maintaining a "Buy" rating. Considering the company's continued delivery of BD transactions in 2026, the bank raises its forecasts, expecting revenue to grow by 11.5%, 13.2%, and 10.4% year-on-year in 2026, 2027, and 2028, respectively, and adjusted net profit attributable to shareholders to grow by 12.5%, 19.4%, and 9.9% year-on-year, respectively. The bank noted that SBP GROUP has recently continued to achieve breakthroughs in both the commercialization and internationalization of innovative drugs. On November 14, 2026, the National Healthcare Security Administration announced the "National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog (2026)," under which SBP GROUP's core enterprise Chia Tai Tianqing had 3 innovative drugs included in the catalog for the first time, new indications for 2 innovative drugs included in the catalog, and 2 innovative drugs successfully renewed. In addition, the company recently reached a platform-type BD collaboration with multinational pharmaceutical company Boehringer Ingelheim (BI), involving US$358 million in upfront and near-term payments, with total potential value of approximately US$7 billion and double-digit sales royalties, extending the strong trend of the company's continued delivery of external collaborations in 2026. The bank believes that the medical insurance expansion is expected to accelerate the commercial conversion of the company's innovative products, while the collaboration with BI validates the value of the company's early research platform and consolidates the long-term growth foundation of its innovative business.